Teriparatide Disease Interactions
There are 6 disease interactions with teriparatide:
- Metabolic bone disorder
- Orthostatic hypotension
- Renal impairment
Parathyroid hormone/analogs (Includes teriparatide) ↔ hyperparathyroidism
Severe Potential Hazard, Moderate plausibility. Applies to: Hyperparathyroidism, Hypercalcemia
Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.
Parathyroid hormone/analogs (Includes teriparatide) ↔ malignancy
Severe Potential Hazard, Moderate plausibility. Applies to: Paget's Disease, Neoplasm of Bone
Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma. These agents should only be used if the potential benefits are considered to outweigh the potential risks. Monitor these patients according to clinical guidelines. Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.
Teriparatide (Includes teriparatide) ↔ metabolic bone disorder
Severe Potential Hazard, Moderate plausibility. Applies to: Paget's Disease, Vitamin D Deficiency, Hungry Bone Syndrome, Osteodystrophy
The use of teriparatide in patients with metabolic bone disease, other than osteoporosis is not recommended by the manufacturer.
Teriparatide (Includes teriparatide) ↔ orthostatic hypotension
Moderate Potential Hazard, Moderate plausibility. Applies to: Hypotension
There have been reports of transient episodes of symptomatic orthostatic hypotension with the use of teriparatide in short-term clinical pharmacology studies. Caution is recommended when using this agent in patients at risk.
Teriparatide (Includes teriparatide) ↔ renal impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
No pharmacokinetic differences were identified in patients with mild or moderate renal impairment after a single dose of teriparatide. In patients with severe renal impairment, the AUC and half-life of teriparatide were increased by 73% and 77%, respectively. Care should be exercised in patients undergoing dialysis for chronic renal failure as no studies have been performed in this patient population.
Teriparatide (Includes teriparatide) ↔ urolithiasis
Moderate Potential Hazard, Moderate plausibility. Applies to: Nephrolithiasis
Teriparatide should be used with caution in patients with active urolithiasis. If active or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered because of the potential to exacerbate urolithiasis in these patients.
Teriparatide drug interactions
There are 38 drug interactions with teriparatide
More about teriparatide
- Side Effects
- During Pregnancy
- Dosage Information
- Patient Tips
- Drug Interactions
- En Español
- 102 Reviews
- Drug class: parathyroid hormone and analogs
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.